Intervention Procedure: PCI
OtherPercutaneous Coronary Intervention
NCT Number: NCT05388357
This study is to establish the primary hypothesis thatAI -QCA guided PCI is non-inferior to Optical coherence tomography-guided Percutaneous coronary intervention regarding minimal Stent area by Final OCT and Procedural MACE
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Not applicable
Sejong General Hospital, Bucheon-si, South Korea
After coronary angiography, AI-QCA software will be used to determine the lesion length and the reference vessel diameter in real time to determine the appropriate stent size for implantation. The procedure is performed as follows:
After coronary angiography, OCT is performed to determine the appropriate stent size for implantation. After the stent procedure, OCT is performed again to check for an area that is smaller than the area of distal reference vessel and for sufficient dilatation. If necessary, high-pressure balloon dilation is performed to minimize residual stenosis. The procedure is performed as follows:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Percutaneous Coronary Intervention
Time frame: 1hour
Minimal Stent Area evaluated by OCT after stenting of the target lesion
Time frame: 24hours
Procedural complications including angiographic dissection, perforation, or acute closure requiring active intervention after stent implantation
Time frame: 24hours
Stent expansion (≥ 90%) in final OCT assessment and successful stent delivery without target-lesion failure in 24 hours
Time frame: 24hours
Stent expansion, stent malapposition, intra-stent tissue (plaque or thrombus) protrusion, untreated reference segment disease
Time frame: 24hours
Minimal lumen diameter at the stented segment, diameter stenosis at the stented segment, acute gain at the stented segment
Time frame: 6month
All-cause death , Cardiac and non-Cardiac death
Time frame: 6month
Any MI( periprocedural/spontaneous MI), Target vessel-MI and non-target vessel-MI
Time frame: 6month
definite/probable
Time frame: 6month
Any revascularization,Target vessel and target lesion revascularization
Time frame: 6month
Composite of all-cause death, myocardial infarction, stent thrombosis, or revascularization
Time frame: 6month
The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
EQ-5D: the minimum and maximum values are 5 and 25 respectively. EQ VAS: the minimum and maximum values are 0 and 100 respectively.
Time frame: 6month
HINT-8 was developed based on 4 health dimensions: physical, mental, social, and positive health dimensions. It consists of climbing stairs, endurance to pain, vitality, working, depression, memory, sleep, and happiness.
Time frame: 6month
Cost-effective analysis based on average treatment costs for two treatment
Asan Medical Center
Other
Fully Automated Quantitative Coronary Angiography Versus Optical Coherent Tomography Guidance for Coronary Stent Implantation (FLASH): Multicenter, Randomized Controlled Non-Interiority Trial
Acronym: FLASH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03401203
Coronary Vessels
Bucheon-si, South Korea
View Trial DetailsNCT00427232
Cardiovascular Diseases, Coronary Disease
Vienna, State of Vienna, Austria
View Trial DetailsNCT03394079
Coronary Vessels
Daegu, South Korea
View Trial DetailsNCT06776224
Amino Acid Metabolism, Inborn Errors, Autoimmune Diseases
Lille, France
View Trial Details